Keith Ligon

Dr. Keith Ligon is an Associate Professor of Pathology at Harvard Medical School, specializing in neuropathology with a focus on gliomas across pediatric and adult populations. His work bridges molecular profiling, precision medicine, and clinical trials for brain tumors.

• Education: PhD and MD from University of Texas Medical School at Houston/MD Anderson (1996-1997), Residency in Anatomic Pathology (Brigham and Women's Hospital, 1999), Fellowship in Neuropathology (Brigham and Women's/Boston Children's Hospital, 2001)
• Certifications: American Board of Pathology (Anatomic & Neuropathology)

Research interests include genomic drivers of glioma progression, immune microenvironment dynamics, mechanisms of therapeutic resistance, and multi-omics approaches for tumor classification. His recent publications highlight single-cell genomics, targeted therapies (e.g., PDGFRA inhibition), and AI-driven diagnostics in brain tumors.

Article trends reveal expertise in glioblastoma, pediatric low-grade/high-grade gliomas, immunotherapy response, and epigenetic regulators like SMARCA4 and IDH-mutant pathways.

Ligon has contributed to 20+ clinical trials in glioblastoma, including platform trials (INSIGhT) for adaptive drug testing, and pioneered intraoperative molecular diagnostics to guide brain tumor surgery.